Xeris exceeds FY2024 revenue guidance with $203M; Q4 positive cash flow; Recorlev up 28% sequentially

Xeris Biopharma Holdings, Inc.

2024-FY EPS reported -$0.37 revenue$203,070,000

Total FY2024 revenue expected at $203M, exceeding prior guidance of $198-202M (24% YoY growth).
Q4 2024 revenue projected at $60M (35% YoY growth); company generated positive cash flow in Q4.
Recorlev net revenue in Q4 anticipated to increase ~$5M or 28% sequentially, with record new starts.
Year-end cash, equivalents, and short-term investments expected to be over $71M.
Amgen terminated XeriJect license per portfolio assessment; no material impact on Xeris outlook.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.